Your browser is no longer supported. Please, upgrade your browser.
AVEO Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.94 Insider Own0.20% Shs Outstand34.37M Perf Week-10.00%
Market Cap113.07M Forward P/E- EPS next Y-0.74 Insider Trans36.30% Shs Float34.32M Perf Month-33.20%
Income-57.60M PEG- EPS next Q-0.25 Inst Own44.70% Short Float3.92% Perf Quarter-48.18%
Sales25.50M P/S4.43 EPS this Y-372.30% Inst Trans-0.04% Short Ratio4.39 Perf Half Y-33.85%
Book/sh1.49 P/B2.30 EPS next Y76.10% ROA-55.30% Target Price17.25 Perf Year-59.24%
Cash/sh2.84 P/C1.20 EPS next 5Y- ROE-105.10% 52W Range3.58 - 18.24 Perf YTD-27.08%
Dividend- P/FCF- EPS past 5Y9.20% ROI-79.20% 52W High-81.25% Beta1.10
Dividend %- Quick Ratio4.80 Sales past 5Y-20.60% Gross Margin89.40% 52W Low-4.47% ATR0.26
Employees49 Current Ratio4.80 Sales Q/Q322.20% Oper. Margin- RSI (14)23.05 Volatility5.97% 5.99%
OptionableYes Debt/Eq0.64 EPS Q/Q7.30% Profit Margin- Rel Volume1.39 Prev Close3.60
ShortableYes LT Debt/Eq0.64 EarningsNov 08 AMC Payout- Avg Volume306.81K Price3.42
Recom1.20 SMA20-23.22% SMA50-37.17% SMA200-44.83% Volume427,599 Change-5.00%
Nov-09-20Initiated Stifel Buy $9
Aug-13-20Initiated SVB Leerink Outperform $7
Sep-11-19Upgrade H.C. Wainwright Neutral → Buy $1.75
Feb-04-19Downgrade B. Riley FBR Buy → Neutral $5 → $1
Feb-01-19Downgrade H.C. Wainwright Buy → Neutral $1
Jan-04-19Initiated Robert W. Baird Outperform
Nov-13-17Initiated B. Riley FBR, Inc. Buy $5
May-19-16Initiated Piper Jaffray Overweight $1.70
Mar-30-16Initiated FBR Capital Outperform $3
Mar-09-15Upgrade RBC Capital Mkts Underperform → Sector Perform $2 → $3
Dec-16-13Downgrade RBC Capital Mkts Sector Perform → Underperform $5 → $2
May-03-13Upgrade Stifel Sell → Hold
May-03-13Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $6
May-03-13Downgrade Canaccord Genuity Buy → Hold $2
Dec-21-12Reiterated RBC Capital Mkts Outperform $18 → $15
Nov-14-12Initiated Stifel Nicolaus Sell
May-04-12Reiterated RBC Capital Mkts Outperform $24 → $19
May-13-11Upgrade MP Advisors Underperform → Market Perform $11 → $20
Nov-30-10Initiated RBC Capital Mkts Outperform $24
Nov-29-10Initiated MP Advisors Underperform $8
Jan-20-22 08:00AM  
Jan-11-22 05:04AM  
Jan-05-22 08:00AM  
Jan-04-22 08:05AM  
Dec-28-21 09:38AM  
Dec-22-21 08:00AM  
Dec-21-21 09:38AM  
Dec-08-21 09:38AM  
Dec-01-21 07:00AM  
Nov-12-21 04:54AM  
Nov-10-21 07:00AM  
Nov-08-21 05:25PM  
Nov-01-21 03:01PM  
Sep-20-21 07:00AM  
Sep-13-21 06:46AM  
Aug-30-21 07:00AM  
Aug-05-21 06:45PM  
Jul-29-21 07:00AM  
Jul-08-21 04:05PM  
Jun-07-21 07:00AM  
May-25-21 07:00AM  
May-19-21 05:02PM  
May-10-21 06:15PM  
May-03-21 07:00AM  
Apr-22-21 12:33PM  
Apr-16-21 07:00AM  
Mar-29-21 07:00AM  
Mar-26-21 04:01PM  
Mar-23-21 10:32PM  
Mar-22-21 04:01PM  
Mar-19-21 08:21AM  
Mar-16-21 05:35PM  
Mar-15-21 10:41AM  
Mar-12-21 12:58PM  
Mar-11-21 04:05PM  
Mar-10-21 05:52PM  
Mar-08-21 12:30PM  
Mar-02-21 07:00AM  
Feb-18-21 07:00AM  
Feb-17-21 04:15PM  
Feb-11-21 07:00AM  
Jan-20-21 07:00AM  
Jan-15-21 08:00AM  
Jan-07-21 07:00AM  
Jan-06-21 07:00AM  
Jan-05-21 07:00AM  
Dec-07-20 08:14PM  
Nov-10-20 07:00AM  
Nov-09-20 06:35PM  
Nov-05-20 07:00AM  
Nov-03-20 12:30PM  
Oct-19-20 07:00AM  
Oct-16-20 09:58AM  
Oct-14-20 10:03AM  
Oct-13-20 08:36AM  
Oct-09-20 12:30PM  
Oct-08-20 11:37AM  
Oct-07-20 10:49AM  
Oct-06-20 08:54AM  
Sep-22-20 08:34AM  
Sep-15-20 04:05PM  
Sep-14-20 08:07AM  
Sep-09-20 12:42PM  
Sep-08-20 01:11PM  
Sep-04-20 12:52PM  
Sep-03-20 07:00AM  
Aug-18-20 12:00PM  
Aug-11-20 08:48AM  
Aug-10-20 07:35PM  
Aug-06-20 12:30PM  
Aug-05-20 04:05PM  
Jul-01-20 09:16AM  
Jun-19-20 04:05PM  
Jun-16-20 10:38PM  
Jun-15-20 04:05PM  
Jun-04-20 07:01PM  
Jun-02-20 11:41AM  
Jun-01-20 01:15PM  
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAILEY MICHAEL PPresident & CEOSep 01Buy6.4815,00097,20049,311Sep 03 05:12 PM
Ferraresso MichaelChief Commercial OfficerAug 10Buy5.752,60814,9968,318Aug 11 07:49 PM